Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial

Summary

This is a phase 2a, randomized, double-blinded, placebo-controlled pilot clinical trial determining the impact of riluzole therapy on circulating brain derived neuropathic factor (BDNF) levels in cancer survivors (recently completing prior treatment regimens) or patients who have received whole brain radiation for benign or malignant tumors with cancer related cognitive impairment.

Timeline

Start

2024-12-02

Primary completion

2027-07

Completion

2027-12

Drugs

Indications